New cocktail of drugs takes on tough pancreatic cancer
NCT ID NCT07488884
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether adding three new drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are hard to remove. About 30 adults with borderline resectable or locally advanced pancreatic cancer will receive the combination before surgery, then continue immunotherapy afterward. The main goal is to check for side effects and see if the treatment helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nogapendekin alfa inbakicept, sotevtamab, zabadinostat, gemcitabine, nab-paclitaxel
What this could lead to
If successful, this could point toward a more effective treatment approach for pancreatic cancer that is hard to remove with surgery alone.
What could go wrong
This is a very early phase 1 trial with only 30 people, focused on safety. The drug combination may cause serious side effects and may not shrink tumors enough to allow surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.